Biblio
Export 751 results:
Author Title Type [ Year
Filters: First Letter Of Last Name is V [Clear All Filters]
“Telomere Length and the Risk of Alzheimer's Disease: The Rotterdam Study.”, J Alzheimers Dis, vol. 73, no. 2, pp. 707-714, 2019.
, “Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons with Global Deterioration Scale Stage 2 (Subjective Cognitive Decline with Impairment).”, J Alzheimers Dis, vol. 67, no. 2, pp. 685-705, 2019.
, “Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 71, no. 3, pp. 775-783, 2019.
, “Vascular Burden Score Impacts Cognition Independent of Amyloid PET and MRI Measures of Alzheimer's Disease and Vascular Brain Injury.”, J Alzheimers Dis, vol. 68, no. 1, pp. 187-196, 2019.
, “Why Is Amyloid-β PET Requested After Performing Cerebrospinal Fluid Biomarkers?”, J Alzheimers Dis, vol. 73, no. 2, pp. 559-569, 2019.
, “Why Is Amyloid-β PET Requested After Performing Cerebrospinal Fluid Biomarkers?”, J Alzheimers Dis, vol. 73, no. 2, pp. 559-569, 2019.
, “Abnormalities of Resting State Cortical EEG Rhythms in Subjects with Mild Cognitive Impairment Due to Alzheimer's and Lewy Body Diseases.”, J Alzheimers Dis, vol. 62, no. 1, pp. 247-268, 2018.
, “Accuracy of Inferred APOE Genotypes for a Range of Genotyping Arrays and Imputation Reference Panels.”, J Alzheimers Dis, vol. 64, no. 1, pp. 49-54, 2018.
, “Acute Stroke Care in Dementia: A Cohort Study from the Swedish Dementia and Stroke Registries.”, J Alzheimers Dis, vol. 66, no. 1, pp. 185-194, 2018.
, “Age-Dependent Decrease of Mitochondrial Complex II Activity in a Familial Mouse Model for Alzheimer's Disease.”, J Alzheimers Dis, vol. 66, no. 1, pp. 75-82, 2018.
, “Albuminuria and Microalbuminuria as Predictors of Cognitive Performance in a General Population: An 11-Year Follow-Up Study.”, J Alzheimers Dis, vol. 62, no. 2, pp. 635-648, 2018.
, “Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies.”, J Alzheimers Dis, vol. 62, no. 3, pp. 965-992, 2018.
, “Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies.”, J Alzheimers Dis, vol. 62, no. 3, pp. 965-992, 2018.
, “Alzheimer's Disease Biomarkers Have Distinct Associations with Specific Hippocampal Subfield Volumes.”, J Alzheimers Dis, vol. 66, no. 2, pp. 811-823, 2018.
, “Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines.”, J Alzheimers Dis, vol. 62, no. 2, pp. 523-547, 2018.
, “Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines.”, J Alzheimers Dis, vol. 62, no. 2, pp. 523-547, 2018.
, “Amsterdam Dementia Cohort: Performing Research to Optimize Care.”, J Alzheimers Dis, vol. 62, no. 3, pp. 1091-1111, 2018.
, “The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade.”, J Alzheimers Dis, vol. 64, no. s1, pp. S567-S610, 2018.
, “Antibodies to Multiple Receptors are Associated with Neuropsychiatric Symptoms and Mortality in Alzheimer's Disease: A Longitudinal Study.”, J Alzheimers Dis, vol. 64, no. 3, pp. 761-774, 2018.
, “Antibodies to Multiple Receptors are Associated with Neuropsychiatric Symptoms and Mortality in Alzheimer's Disease: A Longitudinal Study.”, J Alzheimers Dis, vol. 64, no. 3, pp. 761-774, 2018.
, “Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo.”, J Alzheimers Dis, vol. 65, no. 1, pp. 265-281, 2018.
, “Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo.”, J Alzheimers Dis, vol. 65, no. 1, pp. 265-281, 2018.
, “Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo.”, J Alzheimers Dis, vol. 65, no. 1, pp. 265-281, 2018.
, “Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo.”, J Alzheimers Dis, vol. 65, no. 1, pp. 265-281, 2018.
, “Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo.”, J Alzheimers Dis, vol. 65, no. 1, pp. 265-281, 2018.
,